AbbVie announces Q3 financial results, Humira, psoriasis treatment updates

AbbVie announced in a press release that third-quarter financial results ending Sept. 30 included worldwide reported net revenues of $6.43 billion, up 8.2%.

There were diluted earnings per share of $0.97 on a GAAP basis in the quarter, and adjusted diluted EPS was $1.21 up 7.1%, excluding intangible asset amortization expense and other specified items, according to the release.

There was an increase of global Humira sales of 11.3% on a reported basis, and operational Humira sales increase 12.1%, excluding a 0.8% impact from foreign exchange. Continued momentum across market categories of dermatology, rheumatology and gastroenterology contributed to strong global growth, according to the release.

AbbVie also announced it has completed patient enrollment for a phase 3 pivotal program studying risankizumab in patients with moderate-to-severe plaque psoriasis in partnership with Boehringer Ingelheim. Data from three registrational studies are expected by the end of 2017, according to the release.

The potential of risankizumab for treating Crohn’s disease, psoriatic arthritis and asthma is also being evaluated, according to the release.

Reference: www.abbvie.com